Flavagline analog FL3 induces cell cycle arrest in urothelial carcinoma cell of the bladder by inhibiting the Akt/PHB interaction to activate the GADD45α pathway.
Fiche publication
Date publication
février 2018
Journal
Journal of experimental & clinical cancer research : CR
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DESAUBRY Laurent
Tous les auteurs :
Yuan G, Chen X, Liu Z, Wei W, Shu Q, Abou-Hamdan H, Jiang L, Li X, Chen R, Désaubry L, Zhou F, Xie D
Lien Pubmed
Résumé
Prohibitin 1 (PHB) is a potential target for the treatment of urothelial carcinoma of the bladder (UCB). FL3 is a newly synthesized agent that inhibits cancer cell proliferation by targeting the PHB protein; however, the effect of FL3 in UCB cells remains unexplored.
Mots clés
Cell cycle, FL3, GADD45α, PHB, Urothelial carcinoma of the bladder
Référence
J. Exp. Clin. Cancer Res.. 2018 Feb 7;37(1):21